Page last updated: 2024-11-01

nomifensine and Atrophy

nomifensine has been researched along with Atrophy in 1 studies

Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266)
nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.

Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brooks, DJ1
Salmon, EP1
Mathias, CJ1
Quinn, N1
Leenders, KL1
Bannister, R1
Marsden, CD1
Frackowiak, RS1

Other Studies

1 other study available for nomifensine and Atrophy

ArticleYear
The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.
    Brain : a journal of neurology, 1990, Volume: 113 ( Pt 5)

    Topics: Adult; Aged; Atrophy; Autonomic Nervous System; Autonomic Nervous System Diseases; Brain Diseases; C

1990